2024 ASCO Annual Meeting: HUTCHMED to present new data on fruquintinib & sintilimab in endometrial cancer, supporting NDA in China.
HUTCHMED to present new data on fruquintinib & sintilimab in endometrial cancer at the 2024 ASCO Annual Meeting. New and updated data from a Phase II study of fruquintinib with sintilimab in second-line or above endometrial cancer patients with pMMR status will be presented, supporting the NDA filed in China. The combination demonstrated meaningful efficacy improvements with a manageable safety profile.
May 24, 2024
3 Articles